Trial | NCT00600769  Report issue

Title

Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    210
Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria
Oral clarithromycin for treatment of MAC and other nontuberculous mycobacteria in adults with clinical history
Study Started
Jan 31
1991
Primary Completion
Nov 30
2006
Study Completion
May 18
2017
Last Update
May 23
2017

Drug Clarithromycin

Dosage dependent on clinical factors such as age, weight and patient-specific health status

  • Other names: Biaxin

treatment of MAC and other NTM Other

Clarithromycin drug given twice daily.

Criteria 

Inclusion Criteria:

Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; absence of other potential lung pathogens (except for the coexistence of M. abscessus)
Age 18 years and older

Exclusion Criteria:

History of macrolide allergy
Must not receive the antihistamines terfenadine (Seldane) or astemizole (Hismanal) while on clarithromycin
Children less than 18 years of age
If a menstruating female, not pregnant and on adequate birth control
No Results Posted